I posted it previously. He was scheduled to be
Post# of 30029
(Total Views: 260)
Posted On: 12/12/2017 2:17:20 PM
Re: Both shallow #25580
I posted it previously.
He was scheduled to be on this panel. Looked like some heavy hitters so I was excited.
Innovative Approaches to Parkinson's and Other Movement Disorders Panel
Co-Chaired by:
Kiran Reddy, Venture Partner, Clarus Ventures, LLC
Murali Gopalakrishnan, Senior Director, Search & Evaluation Neuroscience, AbbVie, Inc.
Panelists:
Andrew Hindman, Chief Business Development Officer, Acorda Therapeutics, Inc.
Brian Fiske, SVP, Research Programs, Michael J. Fox Foundation
Damien McDevitt, SVP, Corporate Development, ACADIA Pharmaceuticals, Inc.
Jesse Cedarbaum, VP, Early Clinical Development, Biogen
Kees Been, CEO, Lysosomal Therapeutics
Kenneth Rhodes, CSO, Yumanity Therapeutics
He was scheduled to be on this panel. Looked like some heavy hitters so I was excited.
Innovative Approaches to Parkinson's and Other Movement Disorders Panel
Co-Chaired by:
Kiran Reddy, Venture Partner, Clarus Ventures, LLC
Murali Gopalakrishnan, Senior Director, Search & Evaluation Neuroscience, AbbVie, Inc.
Panelists:
Andrew Hindman, Chief Business Development Officer, Acorda Therapeutics, Inc.
Brian Fiske, SVP, Research Programs, Michael J. Fox Foundation
Damien McDevitt, SVP, Corporate Development, ACADIA Pharmaceuticals, Inc.
Jesse Cedarbaum, VP, Early Clinical Development, Biogen
Kees Been, CEO, Lysosomal Therapeutics
Kenneth Rhodes, CSO, Yumanity Therapeutics
(3)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼